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ABSTRACT  
Objective: The objective of present study was to formulate an oral mcoadhesive tablet of diltiazem hydrochloride.  
Methods: Investigate the effect of amount of HPMC K4M and sodium alginate on the sustained release and gastric residence time of dosage form. 
The mucoadhesive tablet prepared by direct compression method was used varying concentrations of HPMC K4M and Sodium alginate and (1:1, 
1:1.5, 1:2) Drug and Polymer ratio.  
Results: The formulations were evaluated and results revealed that FTIR studies showed no evidence of interactions between drug and excipients 
used. The mucoadhesive strength, residence time and drug content of formulation F3 was found to be 26.35 ± 1.15 mg, >7.5hrs, and 98.75 ± 0.05 % 
respectively. The formulation F3 exhibited sustained drug release i.e. 75.71% in 12 h. The In Vitro release kinetics studies reveal that formulations 
fit well with zero order kinetics and mechanism of drug release is Super case II transport.  
Conclusion: The study was concluded that formulation of mucoadhesive tablets from the cumulative % drug release study reveals that increase in 
the concentration of adhesive polymers cause slow the drug release. Sustained release tablet of DTZ can be beneficial in treatment of hypertension.  
Keywords: Diltiazem Hydrochloride, Mucoadhesive tablet, Sodium alginate, Mucoadhesive strength, In Vitro drug release. 
 
INTRODUCTION 
Oral drug delivery route is the most preferable route of drug 
delivery. It is due to various advantages of this route like ease of 
administration, patient compliance and flexibility in the 
formulations. Oral absorption of drugs is often limited due to short 
gastric retention time. The gastric retention time is 3 to 4 hrs of 
human beings. The retention of drug delivery system in the stomach 
prolongs overall Gastrointestinal (GI) transit time, there by resulting 
in improved bioavailability drugs. However, oral route has certain 
problems such as unpredictable gastric emptying rate, short gastro-
intestinal transit time and existence of an absorption window in the 
gastric and upper small intestine for several drugs [1-2].  
Polymers can be used to control the release of both water soluble 
and water insoluble drugs. On the surface, their drug release 
behavior appears simple, but the drug release pattern is a complex 
phenomenon. At the molecular level, it involves water penetration, 
polymer adhesion as well as drug dissolution, diffusion and polymer 
erosion process [3-6]. Various approaches for gastroretentive 
dosage forms have been proposed including mucoadhesive, 
swellable and floating systems 
The sustained gastric retention of solid dosage forms may be 
achieved by the mechanisms of mucoadhesion, flotation, 
sedimentation, expansion, modified shape system or by the 
simultaneous administration of pharmacological agent that delay 
gastric emptying rate[11-13].  
[7-8]. Diltiazem hydrochloride is a 
calcium channel blocker, which has been used in the treatment of 
cardiovascular disorders, particularly angina pectoris and systemic 
hypertension. It has short biological half life of about 3.5 h and 
rapidly eliminated. It is favorably absorbed from stomach and the 
oral bioavailability is about 40% [9-10]. 
The objective of the present work was to develop mucoadhesive 
tablet of Diltiazem hydrochloride, which after oral administration 
could prolong the gastric residence time and increase its 
bioavailability. After oral administration, such stomach-specific 
mucoadhesive tablets would be retained in the stomach and release 
the drug there in a controlled and prolonged manner, so that the 
drug could be supplied continuously to its absorption sites in the 
upper gastrointestinal tract. This mode of administration would best 
achieve the known pharmacokinetic and pharmacodynamic 
advantages of stomach-specific mucoadhesive tablets for these 
drugs [14-16]. Mucoadhesive tablets are widely used because they 
release the drug for prolong period, reduce frequency of drug 
administration and improve the patient compliance [17]. 
MATERIALS AND METHODS 
Materials 
Diltiazem hydrochloride was procured from Nicholas Piramal Ltd., 
Mumbai. Hydroxy propyl methylcellulose (HPMC K4M) was supplied 
by Colorcon Ltd., Goa, Sodium alginate was gifted by Snap Natural 
and Alginate products Pvt. Ltd., Tamilnadu, Polyvinyl pyrrolidone 
K30 was procured from Spectrochem Pvt. Ltd, Mumbai, and all the 
other chemicals used were of analytical grade. 
Experimental 
Preformulation study 
The sample of Diltiazem hydrochloride was analyzed for its nature, 
color and taste. The melting point was done by capillary tube 
method. Diltiazem hydrochloride was estimated by UV 
spectrophotometry method. 
Infrared spectra analysis
Infrared spectrum of DTZ was determined on Fourier Transform 
Infrared Spectrophotometer (FTIR Shimadzu -4100) using KBr 
dispersion method. The base line correction was done using dried 
potassium bromide. The spectrum of dried mixture of drug and 
potassium bromide (1:100) was obtained.  
  
Compatibility studies 
The FTIR spectra’s are used to identify the drug and detect the 
interaction of drug and polymers. FTIR spectrum of pure drug and 
physical mixture of drug and polymers were obtained on FTIR 
(Shimadzu 4100) instrument. The physical mixture of drug and 
polymers was prepared (1:1) and spectrum of physical mixture and 
potassium bromide (1:100) was obtained. 
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Preparation of mucoadhesive tablet 
The mucoadhesive gastroretentive tablets were prepared by direct 
compression method using rotary tablet machine (Rimek, Mumbai). 
The proportionate composition of various ingredients was given in 
table 1. The hydrophilic polymers like HPMC K4M and Sodium 
alginate were used as mucoadhesives agents in the formulation. 
Lactose and Polyvinyl pyrrolidone K30 were used as diluents and 
binder respectively. Magnesium stearate and Ethyl cellulose were 
used as lubricant and as backing layer. All ingredients were mixed 
thoroughly and the tablets were directly compressed by using a 
rotary tablet machine of 13 mm punch size. 
Characterization of granules properties 
The granules were evaluated for their characteristic parameters, 
such as bulk density, tapped density, Carr’s index and angle of 
repose. Carr’s compressibility index was calculated from the bulk 
and tapped densities using a digital tap density apparatus 
(Electrolab Ltd, India) [18-19]. 
Compression of tablet 
The quantity of excipients was compressed lightly using a minipress 
rotatory tablet machine, equipped with 10 mm round, flat and plain 
punches for core tablet and bilayer coating with ethyl cellulose by 
using 13 mm punches size.  
Physical tests for the tablets 
The standard physical tests for the tablets were performed and 
average weight was calculated. Thickness and diameter were 
measured using vernier caliper. Hardness was determined by using 
a Monsanto hardness tester (Electrolab Pvt. Ltd., India) and the 
average of pressure (kg/cm2
Friability was determined by using friability tester apparatus (Veego 
Pvt. Ltd., India), which was rotated for 4 min at 25 rpm. After 
dusting, the total remaining mass of the tablets was recorded and 
the percent friability was calculated. 
) applied for crushing the tablet was 
determined.  
Drug content uniformity 
Ten tablets were finely powdered and an amount equivalent to 10 
mg was accurately weighed and dissolved in 10 ml 0.1N HCl with the 
help of sonication for 20 min. The resulting solution was further 
diluted with 0.1N HCl to achieve concentration up to 10 μg/ml and 
the absorbance measured at the 237 nm using double beam UV 
spectrophotometer.
 
Table 1: Composition of Mucoadhesive Tablets of DTZ. 
Ingredients Batches codes 
F1 F2 F3 F4 F5 F6 
DTZ HCl 100 100 100 100 100 100 
HPMC K4M 100 150 200 _ _ _ 
HPMC E15 _ _ _ 100 150 200 
Sodium alginate 125 75 25 125 75 25 
Lactose 70 70 70 70 70 70 
PVP k30 60 60 60 60 60 60 
Magnesium stearate 5 5 5 5 5 5 
Core tablet 460 460 460 460 460 460 
Layer 2 EC 100 100 100 100 100 100 
Total weight 560 560 560 560 560 560 
 
In Vitro drug release study  
The In Vitro dissolution was carried out by using Dissolution Testing 
apparatus type II. The tablet was placed to the dissolution medium 
(900 ml) of 0.1N HCl. Dissolution medium temperature was 
maintained at 37°C and stirring at 100 rpm. An aliquot of the sample 
(5 ml) was periodically withdrawn at hourly for 12 hours and the 
volume was replaced with fresh dissolution medium. The samples 
were analyzed spectrophotometrically at 237 nm. The cumulative 
percentage drug release was calculated [20-23].  
Ex- vivo mucoadhesive characteristics 
Ex vivo mucoahesive strength 
The working of a double beam physical balance formed the basis of 
the mucoadhesion test. The two pan of a physical balance was 
removed and replaced with a same volume of beakers hanged with a 
lightweight thread. The height of this total set-up was adjusted to 
accommodate a glass petriplate below it, leaving a head space of 
about 0.5 cm in between petriplate and left beaker. The two sides 
were then balanced. The sheep mucus membrane was excised and 
washed (equilibrated at 37ºC ± 1ºC for 30 min in 0.1N HCl medium 
before the mucoadhesion evaluation study) and tied tightly with the 
thread to mucus on glass side, which was then filled with 0.1N HCl 
kept at 37ºC ± 1ºC, such that 0.1N HCl just reaching the surface of 
mucosal membrane and keeping it moist. This was then kept below 
the left beaker and the left beaker was then lowered into the 
petriplate of the balance. The tablet was then stuck to the bottom of 
left beaker, using two way adhesive and the balance beam. A 
constant weight of 10 gm was then placed over the left beaker for 
the total contact of tablet to mucus for a period of 5 min. 
Mucoadhesive strength was then assessed by adding weights on the 
right beaker till the tablet separated from the mucosal surface, in 
terms of the weight (in gm) required to detach tablet from the 
membrane. The modified physical double beam balance was shown 
in figure 1 [25-26]. 
 
Fig. 1: Modified physical double beam balance 
 
Ex vivo residence time 
The ex vivo residence time was carried out by using disintegration 
test apparatus. The disintegration medium was composed of 800 ml 
of 0.1N HCl maintained at 37°C. The sheep stomach mucosa or 
epithelial cell was tied to the surface of a glass slab using thread, 
vertically attached to the apparatus. The mucosal tablet was 
hydrated from one surface using 0.5 ml of 0.1N HCl and then the 
hydrated surface was brought in contact with the mucosal 
membrane. The glass slide was vertically fixed to the apparatus and 
allowed to run in such way that the tablet completely immersed in 
the 0.1N HCl at the lowest point. and was out at the highest point.  
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The time taken for complete erosion or dislodgment of the tablet 
from the mucosal surface was noted. Disintegration test apparatus 
was shown in figure 2 [27]. 
 
Fig. 2: Disintegration test apparatus 
 
Differential scanning calorimetry (DSC) 
The Differential Scanning Calorimetric analysis was carried out 
using SDT 2960 TA Instrument, USA, Differential Scanning 
Calorimeter. Samples were placed in a platinum crucible and the 
DSC thermograms were recorded at a heating rate of 10ºC/min in 
the rage 20º to 350 ºC, at a nitrogen flow of 20 ml/min [28]. 
Powder x-ray diffraction (PXRD) 
The Powder X ray Diffraction (PXRD) was carried out using Philips 
X-ray diffracto-meter, PW-3710, Holland, using Cu Kα radiation (λ = 
1.5405 Å) at voltage of 40 kV, and 30 mA current. The data recorded 
over a range of 10°c to 50°c at a scanning rate of 5×103 cps using a 
chart speed of 5 mm/2°c [29-30]. 
Scanning electron microscopy  
The morphology of the surface of tablet before and after dissolution 
was studied for understands the mechanism of drug release and 
expansion by using scanning electron microscopy. The intact tablet 
was scanned before and after dissolution for 6 hours, tablet was 
removed and dried to remove water content.  
The sample was coated with a gold-palladium target using a Navatec 
(JEOL JSM-6360 SEM, Japan) vacuum evaporator for 1 hour. SEM 
image was obtained at an acceleration voltage of 8 to 10 kV. [34-35]. 
Stability study  
The batch F3 was selected as an optimized batch for the stability 
study. Five tablets were individually wrapped using aluminum foil 
and packed in amber color screw cap bottle and kept at specified 
conditions of 40 °C at 75 % RH for the period of three months. The 
dissolution profile was analyzed after three months [36]. 
RESULT AND DISCUSSION 
The sample of Diltiazem hydrochloride was crystalline powder 
having off white to white color, odorless and bitter in taste. The 
melting point was observed in the range of 212°C– 215°C. The 
standard solution of Diltiazem hydrochloride was scanned through 
200-400 nm regions on Jasco V-530 UV spectrophotometer. The 
Diltiazem hydrochloride absorption maximum was found to be 237 
nm. FTIR spectrum of pure drug was found to be similar to that of 
standard spectrum of DTZ. It showed characteristics peaks 
belonging to measure functional groups shown in figure 3. 
 
Fig. 3: FTIR spectral analysis of DTZ 
 
Compatibility Studies 
FTIR studies revealed that the fundamental peaks of the DTZ HCl are 
retained in the physical mixture. Results showed that there exist no 
chemical interaction between DTZ HCl and polymer and excipients, 
hence; these can be used in the formulation of mucoadhesive tablet 
of DTZ HCl. Overlain spectrums of pure drug (DTZ HCl), HPMC K4M, 
and physical mixture of drug and polymer were shown in figure 4. 
 
Fig. 4: Overlain FTIR spectrums of DTZ, HPMC K4M, PM 
(physical mixture) 
 
Evaluation of powder properties 
The bulk density of powder mixture was found to be between 
0.3105 ± 0.04 to 0.3408 ± 0.02 g/cm3
 
. This indicates good packing 
capacity of powder. Carr’s index was found to be between 16.56 ± 
0.04 to 20.13 ± 0.10 % show good flowability. Hausner’s ratio was 
less than 2 that indicates good flowability. The angle of repose was 
in range of 18.08 ± 0.17 to 20.13 ± 0.10 % show excellent flowability 
of the powder mixture. The powder properties of DTZ tablet 
formulation shown in table 2. 
Table 2: Powder properties of all batches 
Batch code Bulk density (g/cm3 Tapped density (g/cm)* 3 Carr’s Index (I)* C Hausner’s Ratio (H)* R Angle of Repose (θ)* )* 
F1 0.3335 ± 0.04 0.4176 ± 0.04 20.13 ± 0.10 1.25 ± 0.02 19.76 ± 0.14 
F2 0.3262 ± 0.01 0.3958 ± 0.01 17.58 ± 0.12 1.21 ± 0.04 19.46 ± 0.14 
F3 0.3125 ± 0.04 0.3850 ± 0.02 18.83 ± 0.02 1.20 ± 0.04 18.36 ± 0.12 
F4 0.3408 ± 0.02 0.4166 ± 0.04 18.19 ± 0.06 1.22 ± 0.03 17.67 ± 0.13 
F5 0.3309 ± 0.01 0.3966 ± 0.03 16.56 ± 0.04 1.19 ± 0.06 18.08 ± 0.17 
F6 0.3105 ± 0.04 0.3846 ± 0.02 19.26 ± 0.04 1.23 ± 0.02 21.96 ± 0.14 
∗ Indicates average reading ± SD (n = 3) 
 
Evaluation of mucoadhesive tablets of DTZ 
The average weight of tablets and thickness were ranged from 558.1 
± 1.6 to 560.5 ± 0.7 mg and 4.03 ± 0.07 to 5.75 ± 0.05 mm 
respectively. The diameter and hardness were ranged in between 
13.01 ± 0.01-13.10 ± 05 mm and 7.15 ± 0.5 to 8.40 ± 0.2 kg/cm2. The 
friability was in range of 0.0026 ± 0.04 to 0.0053 ± 0.04 %. Drug 
content was in range of 97.15 ± 0.15 to 99.45 ± 0.05 indicating good 
content uniformity in the prepared formulation. The values of 
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uniformity of weight, thickness, diameter, hardness, friability, drug content from batch F1 to F6 are shown in table 3. 
  
Table 3: Tablet properties of DTZ mucoadhesive tablets 
Batch code Average wt (mg)* Thickness (mm)* Diameter  
(mm)* 
Hardness (kg/cm2)* Friability  
(%)* 
Drug content (%)* 
F1 558.5 ± 1.5 4.83 ± 0.02 13.02 ± 0.04 7.35 ± 0.15 0.0053 ± 0.02 98.65 ± 0.05 
F2 559.5 ± 1.0 4.85 ± 0.05 13.01 ± 0.01 7.15 ± 0.40 0.0035 ± 0.05 97.60 ± 0.15 
F3 560.1 ± 0.6 4.88 ± 0.02 13.01 ± 0.03 8.33 ± 0.20 0.0026 ± 0.04 98.75 ± 0.05 
F4 559.5 ± 0.8 4.85 ± 0.05 13.05 ± 0.05 8.44 ± 0.10 0.0035 ± 0.05 97.15 ± 0.15 
F5 558.1 ± 1.6 4.80 ± 0.04 13.01 ± 0.01 7.27 ± 0.25 0.0053 ± 0.04 98.45 ± 0.10 
F6 560.5 ± 0.7 4.86 ± 0.04 13.03 ± 0.08 8.31 ± 0.20 0.0026 ± 0.04 99.45 ± 0.05 
∗ Indicates average reading ± SD (n = 3) 
 
In Vitro drug release study 
The In Vitro dissolution study, was concluded that release drug from 
the matrix is largely dependent on the polymer adhesion, drug 
diffusion and matrix erosion. It was observed that all the tablets 
were having lag time for first one hour and after first hour it adhere 
until the complete of release studies. The drug release study was 
carried out under specified conditions up to 12 hrs. The cumulative 
% drug release of F1 to F6 batch was in the range 75.71 ± 1.12 to 
91.52 ± 1.08 %. The higher concentration of polymer resulted in the 
retardation or decreases the drug release. The batch F3 showed 
75.71 ± 0.29 % for 12 hrs, which shows sustained release pattern. 
Hence, batch F3 was selected as optimized batch considering 
sustained release of drug. The cumulative % drug release of batch F1 
to F6 shown in figure 5 
 
Fig. 5: In Vitro drug release of batch F1 to F6 
 
The mean diffusional exponent values (n) ranged from 1.1439 to 
1.3404 indicating that all the formulations presented a dissolution 
behavior controlled by Super case II transport. While the kinetic 
constant (k) ranged from 3.1300 to 5.7320 indicating that DTZ 
release from hydrophilic binder matrices followed super case II 
transport. The correlation coefficient revealed that zero order 
models were better applicable to release data for all the batches. The 
release kinetic model was shown in table 4. 
 
Table 4: Release kinetics model of batch F1 to F6 
Batch 
code 
N k R Best fit model 
F1 1.1439 5.7320 0.9922 Zero Order 
F2 1.2707 4.3341 0.9921 Zero Order 
F3 1.3174 3.1300 0.9897 Zero Order 
F4 1.2484 4.6828 0.9937 Zero Order 
F5 1.3404 3.7147 0.9924 Zero Order 
F6 1.3282 3.4315 0.9902 Zero Order 
 
Ex-vivo mucoadhesive strength and residence time 
determination 
The mucoadhesive strength and residence time was in the range of 
17.15 ± 2.35 to 26.35 ± 1.15 gm and < 5.5 hrs to > 7.5 hrs 
respectively. The values of mucoadhesive strength and residence 
time were shown in table 5.  
 
Table 5: Ex-vivo mucoadhesive strength and residence time 
Batch no. Mucoadhesive Strength (gm) ∗ Residence Time 
(in hr) 
F1 18.20 ± 2.30 < 6.0 hrs 
F2 23.80 ± 1.20 < 7.0 hrs 
F3 26.35 ± 1.15 > 7.5 hrs 
F4 17.15 ± 2.35 < 5.5 hrs 
F5 22.65 ± 2.15 < 6.5 hrs 
F6 25.45 ± 1.05 < 7.0 hrs 
∗ Indicates average reading ± SD (n = 3) 
 
Fourier Transfer Infra Red 
FTIR studies revealed that the fundamental peaks of the DTZ HCl 
were retained in the optimized formulation and physical mixture. 
The results showed that no chemical interaction between DTZ HCl 
and excipients used in the formulation. Overlain spectrums of pure 
drug DTZ HCl, HPMC K4M, physical mixture and optimized batch F3 
were shown in figure 6. 
Spectrophotometer  
 
Fig. 6: Overlain FTIR spectrums of DTZ, HPMC K4M, optimized 
 
batch F3, PM (physical mixture) 
Differential scanning calorimetry  
The thermogram of pure DTZ HCl shows sharp endothermic peak 
starting at 209 °C with melting peak at 214.10°C and in the 
thermogram of optimized batch, endothermic peak was obtained at 
212.60°C. Slight shifting of endothermic peaks with decrease in its 
intensity indicates somewhat reduce crystallinity of drug. Another 
peak observed in formulation at 74.70 °C may be due to polymers 
present in it. Thermographs of DTZ HCl and optimized tablet shown 
in figure 7. 
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Fig. 7: DSC overlain of (A) DTZ, (B) batch F3 
 
Powder X-ray diffractometry 
Powder X-ray diffraction study reveals that the intensity of the 
peaks for the pure drug was sharp, but when it was incorporated 
 
Fig. 8: PXRD Overlain of DTZ (A), physical mixture (B), 
optimized batch F3(C) 
into the polymer matrix, the intensities of the peaks decreases due 
to decreased crystallinity of the DTZ HCl.  
Thus, it was observed that reduction in the crystallinity of drug in 
the optimized batch F3. The overlain of PXRD pattern of DTZ HCl, 
physical mixture and optimized batch F3 has been shown in figure 8. 
Scanning electron microscopy 
The SEM photomicrograph of the tablets after dissolution showed a 
highly porous tablet surface and also reflects a porous tablet matrix 
structure. This would facilitate diffusion of drug from the tablet core 
to the surface. The formation of both pores and gel structure on the 
tablet surface indicates involvement of both erosion and diffusion 
mechanisms for sustained drug release. The SEM images of the 
tablet were taken before and after dissolution shown in figure 9. 
    
Fig. 9: SEM of optimized batch F3 before dissolution (A) and 
after dissolution (B) 
 
Stability study 
The stability study was carried out at accelerated conditions of 40oC 
/ 75% RH for three months. There was no change in physical 
appearance in the optimized batch F3 over a period of three months. 
There was no significant 
 
change in the percentage release of drug 
after three months indicating that stable the formulation. The results 
of stability study after three months were shown in table 8. 
Table 8: Cumulative % drug release for stability study of batch F3 
Time 
(hour) 
Cumulative % Drug 
Release (Initial) ∗ 
Cumulative % Drug Release 
(After 1 months) ∗ 
Cumulative % Drug Release 
(After 2 months) ∗ 
Cumulative% Drug Release 
(After 3 months) ∗ 
1 0.27 ± 0.06 0.25 ± 0.04 0.22 ± 0.03 0.18 ± 0.02 
2 3.32 ± 0.18 3.12 ± 0.15 3.08 ± 0.12 2.98 ± 0.12 
3 6.86 ± 0.50 6.12 ± 0.18 6.04 ± 0.26 5.89 ± 0.11 
4 12.06 ± 1.20 11.48 ± 1.12 11.39 ± 1.06 11.08 ± 1.12 
5 26.26 ± 1.20 26.12 ± 1.04 25.98 ± 1.02 25.76 ± 1.14 
6 34.39 ± 1.01 34.10 ± 1.21 33.96 ± 1.14 33.69 ± 1.11 
7 44.01 ± 1.09 43.75 ± 1.25 43.68 ± 1.32 43.41 ± 1.19 
8 47.44 ± 0.56 47.26 ± 0.62 47.09 ± 0.51 46.89 ± 0.31 
9 53.71 ± 1.04 53.60 ± 1.01 53.37 ± 1.13 53.13 ± 1.07 
10 60.73 ± 1.27 60.15 ± 1.07 60.03 ± 1.07 59.84 ± 1.16 
11 68.80 ± 1.20 68.33 ± 1.17 68.18 ± 1.12 68.02 ± 1.08 
12 75.71 ± 1.12 75.47 ± 1.13 75.23 ± 1.17 75.09 ± 1.11 
∗ Indicates average reading ± SD (n = 3) 
 
CONCLUSION 
The present study was to formulation of mucoadhesive tablets using 
direct compression method. In Vitro dissolution study the results 
reveal that increase in the concentration of adhesive polymers leads 
to sustained release of drug. For the sustained release of drug, 
optimum level of concentrations of polymers are required. DTZ 
release from hydrophilic matrices indicated Super case II transport 
and the best fit model for all batches was Zero order model. It was 
concluded that the development mucoadhesive gastroretentive, 
once a day sustained release tablet of DTZ, can be beneficial in 
treatment of hypertension.  
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